Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics announced a non-binding Letter of Intent for a clinical trial of TT-4 in mesothelioma, sponsored by ADDRI in Australia [1][2] - The trial aims to enroll approximately 50 patients and addresses the urgent need for second-line therapies in mesothelioma, where current outcomes are poor [2][5] - Cyncado will provide TT-4 and limited support under a definitive agreement, as part of an international program alongside U.S. activities [2] Clinical Trial Details - The investigator-initiated trial will evaluate TT-4, a selective A2B receptor antagonist, in mesothelioma patients [1][2] - The trial is led by A/Prof Steven Kao and Dr. Melvin Chin, both specialists in mesothelioma care and research [3][4] - The trial is significant due to Australia's high per-capita burden of mesothelioma, making it a compelling location for research [2][6] Company Background - Cyncado Therapeutics is focused on developing small molecule adenosine receptor antagonists to overcome immune suppression in oncology, with TT-4 as its lead program [11] - The company aims to advance TT-4 toward first-patient dosing in Q1 2026, with a focus on generating decision-quality data for better patient outcomes [11][2] - ADDRI is a not-for-profit research institute dedicated to reducing the impact of asbestos-related diseases and is recognized as a WHO Collaborating Centre [6]

Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented new findings at the AACR-NCI-EORTC conference, demonstrating the anti-tumor activity of their selective A2B receptor antagonist TT-4 in mesothelioma models, with plans for first-patient dosing in Q1 2026 [1][4][10] Group 1: Research Findings - The study provides evidence that selective adenosine A2B receptor inhibition has a direct anti-tumor effect in mesothelioma cells, reducing PD-L1 expression and pCREB levels, and modulating YAP signaling [1][2][3] - In preclinical models, TT-4 showed superior monotherapy activity compared to anti-PD-1, and the combination of TT-4 with anti-PD-1 further enhanced tumor control and immune infiltration [2][3] - In human mesothelioma spheroid systems, hypoxia-linked adenosine signaling was found to increase tumor growth and PD-L1 expression, while TT-4 effectively reduced cell growth and PD-L1 protein levels [3] Group 2: Clinical Development - TT-4 is advancing towards first-patient dosing scheduled for Q1 2026, with the current data supporting its clinical translation [4][10] - The clinical program is focused on targeting known checkpoint resistance pathways to improve treatment responses and patient quality of life [9][10] Group 3: Company Overview - AlphaTON Capital is a digital asset treasury company that also engages in drug development, focusing on oncology and immunotherapy assets [6][9] - Cyncado Therapeutics is developing small molecule adenosine receptor antagonists, with TT-4 being the lead program aimed at overcoming immune suppression in oncology [10]